This message contains images. If you don't see images, click here to view.
Advertise in this news brief.
|
|
|
|
Random mutations may account for two-thirds of cancer risks
The New York Times
It may sound flippant to say that many cases of cancer are caused by bad luck, but that is what two scientists suggested in an article published last week in the journal Science. The bad luck comes in the form of random genetic mistakes, or mutations, that happen when healthy cells divide. Random mutations may account for two-thirds of the risk of getting many types of cancer, leaving the usual suspects — heredity and environmental factors — to account for only one-third, say the authors, Cristian Tomasetti and Dr. Bert Vogelstein, of Johns Hopkins University School of Medicine.
|
|
Share this article:
    |
|
|
Late-breaking abstract submissions open until Feb. 5
SGO is accepting late-breaking abstract submissions for the Annual Meeting on Women’s Cancer® now through Feb. 5, 2015. This session will highlight data of the highest scientific impact that has become available since the original 2015 Annual Meeting abstract submission deadline on Sept. 17, 2014. Abstracts already submitted in response to the original Call for Abstracts for the 2015 Annual Meeting are not eligible for resubmission.
Neoadjuvant chemotherapy for ovarian cancer
OncLive
Current practice for the treatment of ovarian cancer involves primary de-bulking surgery followed by chemotherapy. Neoadjuvant chemotherapy, or the delivery of chemotherapy before surgery, tends to be used in patients who are not candidates for upfront de-bulking surgery, observes James Tate Thigpen, MD, and Robert A. Burger, MD.
Advertisement
PRODUCT SHOWCASE
 |
|
ChemoFx® provides invaluable information to physicians choosing from 20+ equivalent treatment recommendations without prior knowledge of how individual patients may respond. ChemoFx determines platinum resistance in primary ovarian cancer and demonstrates longer overall survival by 14 months in recurrent ovarian cancer, making it instrumental in improving patient outcomes.
|
|
Cytoreductive surgery for ovarian cancer
OncLive
Individuals with ovarian cancer who have been treated to the point of no visible residual disease have demonstrated better survival outcomes in clinical trials. Warner K. Huh, MD, acknowledges that although there is a risk of morbidity in pursuing this outcome, achieving zero-volume disease is the goal of surgery.
Evidence of effective delivery of the HPV vaccine through a publicly funded, school-based program
Medscape (Free login required)
Proper administration of the human papillomavirus (HPV) vaccine (three doses at 0, 2, and 6 months) will likely influence the vaccine's effectiveness and the impact of vaccination programs on health outcomes. BMC Public Health recently published a study in which researchers assessed HPV vaccine series completion and on-time dosing in Canada's largest publicly funded, school-based HPV vaccination program.
Are we ready for a paradigm shift in cancer investigation?
Clinical Oncology
Author Maurie Markman, MD, writes: At times it appears that a week does not go by without a report in a high-impact journal strongly suggesting that the “standard of care” for a cancer in a particular clinical setting must change based on the unique molecular biology in a subset of patients. Of course, any reported finding requires confirmation, and some have questioned the overall clinical impact of this ongoing evolution in the understanding of the role of “driver abnormalities” in individual cancers; however, the acceleration in the rate of discovery of useful (“actionable”) data that can be employed in routine cancer care is simply staggering.
Atypical hyperplasia linked to high lifetime risk of breast cancer
Medical News Today
Researchers have long known that atypical hyperplasia — an accumulation of abnormal cells in the ducts or lobules of the breast — can increase a woman's risk of breast cancer. But a new study by researchers from the Mayo Clinic finds that this risk may be higher than previously thought.
Decreased fat intake may offer additional benefit for breast cancer survivors
Healio
Beverly Moy, MD, MPH, clinical director of the breast oncology program at the Massachusetts General Hospital Cancer Center and a HemOnc Today Editorial Board member, highlights results from the from the Women's Intervention Nutrition Study (WINS) which found that early-stage breast cancer patients who reduced their dietary fat intake for five years following a diagnosis had significantly reduced rates of all-cause mortality.
|
|
|
|
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063
|
